Changes in the Polish Market

This free white paper from Datamonitor Healthcare explores changes in the market access environment in Poland. An increasingly important European market, the Polish pharmaceutical market has recently undergone many changes. The Reimbursement Act, introduced in 2012, has had a negative impact on the reimbursed market segment in terms of changes in the reference pricing system and price renegotiation. However, the pricing and reimbursement process is now more transparent and predictable, and the introduction of risk-sharing schemes opens up opportunities for market access to high-cost therapies.

Highlights in this white paper include:

A discussion of the key measures of the Reimbursement Act of 2012 and their impact on the pharmaceutical market.
An analysis of the changes in the rate of addition of new medicines to reimbursement lists.
Insight into how risk-sharing schemes are used in Poland.

Changes in the Polish Market Whitepaper

Total pharmaceuticalsalesinPoland reached €5.0bn($6.6bn)in 2012,with key drivers of the market being the country's growing economy,increasing life expectancy, and an increase in per capita physician visits, offering substantial market potential for pharmaceutical products

Download whitepaper

Next steps

Request a Demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 212-600-3520
UK & Europe : +44 (20) 805 20700
Australia : +61 2 8705 6907

Or please submit your inquiry via the form so that we can provide you the best possible customer service.